Sungkyunkwan University (SKKU)

The Liver Tumor Segmentation Benchmark (LiTS) (2023) Bilic P, Christ P, Li HB, Vorontsov E, Ben-Cohen A, Kaissis G, Szeskin A, et al. Journal article HAWC Detection of a TeV Halo Candidate Surrounding a Radio-quiet Pulsar (2023) Albert A, Alfaro R, Arteaga-Velázquez JC, Ayala Solares HA, Belmont-Moreno E, Capistrán T, Carramiñana A, et al. Journal article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY (2023) Balmaña J, Fasching P, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, et al. Journal article High-altitude characterization of the Hunga pressure wave with cosmic rays by the HAWC observatory (2023) Alfaro R, Alvarez C, Arteaga-Velázquez JC, Kollamparambil Paul AB, Rojas DA, Ayala Solares HA, Babu R, et al. Journal article Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study (2022) Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Treatment of advanced heart failure in adults with congenital heart disease: a narrative review and clinical cases (2022) Sinning C, Huntgeburth M, Fukushima N, Tompkins R, Huh J, Tataneo S, Diller GP, et al. Journal article, Review article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, et al. Conference contribution KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022) Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution